'Pharma Bro' Shkreli Hit With 1st Private Antitrust Suit
By Bryan Koenig (March 4, 2021, 7:20 PM EST) -- Blue Cross and Blue Shield's Minnesota unit hit Martin Shkreli on Thursday with what appears to be the first proposed private antitrust class action against the incarcerated "pharma bro," following in the wake of a 2020 Federal Trade Commission case that made similar claims.
BCBSM Inc.'s lawsuit in New York federal court hews closely to the allegations filed by the FTC and seven attorneys general. It seeks damages against Shkreli, his company Vyera Pharmaceuticals LLC — formerly Turing Pharmaceuticals — Vyera's parent company, Phoenixus AG, and Phoenixus' ex-chairman Kevin Mulleady.
The insurer said that Shkreli monopolized the market for life-saving anti-parasitic drug Daraprim...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!